Numinus Wellness (TSXV: NUMI) is undertaking further studies of its psilocybin products. The company this morning announced a partnership with KGK Science, whereby it will begin studying a psilocybin extract produced in its lab.

The clinical trial is to study the safety and psychoactive properties of a Psilocybe mushroom product that has been extracted and formulated by the study. Classified as a phase 1 trial, the trial is to consist of 14 volunteers that will be used to assess the safety and efficacy of such a product, which will then be used in further trials, or under compassionate-use guidelines.

The study is expected to create IP for the company while also enabling further studies to be conducted in the future.

Numinus Wellness last traded at $1.08 on the TSX Venture.


Information for this briefing was found via Sedar and Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

The post Numinus Wellness To Undertake Phase 1 Study Of Psilocybin Extract appeared first on the deep dive.